ERBB2 and breast cancer: Among the targeted therapies used against breast cancer are trastuzumab, lapatinib, TDM-1, and pertuzumab, which target human epidermal growth factor receptor 2 (HER2) [7]; bevacizumab, which blocks vascular epidermal growth factor receptor (anti-VEGF) and results in reduced tumor angiogenesis [8]; and panitumumab, which blocks epidermal growth factor receptor (anti-EGFR) and inhibits tumor growth by inhibition of cell survival pathways [9].